FDA expands Skyrizi to children as AbbVie introduces weight-based 55 mg dose
AbbVie has secured a broad pediatric label for Skyrizi, adding both plaque psoriasis and active psoriatic arthritis alongside a new dose for children weighing less than 40 kg. The approval could strengthen treatment choice, although the evidence supporting the two indications is not equally direct.
